ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+11.49%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$5.41B
AUM Growth
+$5.41B
(+7%)
Cap. Flow
+$68.8M
Cap. Flow
% of AUM
1.27%
Top 10 Holdings %
Top 10 Hldgs %
72.74%
Holding
42
New
2
Increased
11
Reduced
7
Closed
3
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$59.4M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$46.5M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$32.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$23M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$21.9M |
Top Sells
| 1 |
SPDR S&P Biotech ETF
XBI
|
$66.8M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$51M |
| 3 |
Sarepta Therapeutics
SRPT
|
$23.8M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$21.9M |
| 5 |
Kura Oncology
KURA
|
$17.4M |
Sector Composition
| 1 | Healthcare | 99.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $692M | 12.78% | 10,125,000 +320,000 | +3% | +$21.9M |
|
2
United Therapeutics
UTHR
$13.8B
| $613M | 11.32% | 2,926,500 -43,500 | -1% | -$9.11M |
|
3
argenx
ARGX
$43.6B
| $447M | 8.25% | 1,265,555 | – | – |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $388M | 7.16% | 5,550,555 | – | – |
|
|
5
Sarepta Therapeutics
SRPT
$1.78B
| $351M | 6.48% | 3,175,000 -215,000 | -6% | -$23.8M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $317M | 5.86% | 5,125,000 +125,000 | +3% | +$7.74M |
|
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $301M | 5.57% | 3,555,555 +271,555 | +8% | +$23M |
|
|
8
Ascendis Pharma
ASND
$11.8B
| $294M | 5.44% | 2,850,000 +575,000 | +25% | +$59.4M |
|
9
Amicus Therapeutics
FOLD
$2.34B
| $280M | 5.17% | 26,800,000 | – | – |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $255M | 4.71% | 1,865,000 +340,000 | +22% | +$46.5M |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $221M | 4.09% | 1,105,000 -255,000 | -19% | -$51M |
|
12
Xenon Pharmaceuticals
XENE
$2.98B
| $177M | 3.27% | 4,900,000 | – | – |
|
|
13
BioCryst Pharmaceuticals
BCRX
$1.74B
| $114M | 2.11% | 9,050,000 +2,550,000 | +39% | +$32.1M |
|
|
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $106M | 1.96% | 5,900,000 -1,220,000 | -17% | -$21.9M |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $99.8M | 1.84% | 1,535,000 | – | – |
|
16
Krystal Biotech
KRYS
$4.27B
| $88.9M | 1.64% | 1,275,000 +200,000 | +19% | +$13.9M |
|
17
Iovance Biotherapeutics
IOVA
$807M
| $86.4M | 1.6% | 9,020,000 -200,000 | -2% | -$1.92M |
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $53.4M | 0.99% | 2,222,222 | – | – |
|
19
Mersana Therapeutics
MRSN
$36.5M
| $51M | 0.94% | 7,550,000 | – | – |
|
|
20
Kura Oncology
KURA
$686M
| $48.2M | 0.89% | 3,525,000 -1,275,000 | -27% | -$17.4M |
|
21
Kymera Therapeutics
KYMR
$2.95B
| $47.2M | 0.87% | 2,169,230 +909,230 | +72% | +$19.8M |
|
|
WHWK
22
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $40.3M | 0.74% | 2,849,402 +1,020,000 | +56% | +$14.4M |
|
23
Design Therapeutics
DSGN
$315M
| $37.2M | 0.69% | 2,222,222 | – | – |
|
24
PMV Pharmaceuticals
PMVP
$74.2M
| $36.4M | 0.67% | 3,060,000 -40,000 | -1% | -$476K |
|
|
CBAY
25
DELISTED
Cymabay Therapeutics
CBAY
| $36.1M | 0.67% | 10,300,000 | – | – |
|